Dyne Therapeutics (NASDAQ:DYN) Sets New 12-Month Low – Here’s What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $11.33 and last traded at $11.50, with a volume of 1605555 shares trading hands. The stock had previously closed at $12.40.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on DYN. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. HC Wainwright reduced their price objective on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Chardan Capital reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Friday, February 28th. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Finally, Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $48.75.

Dyne Therapeutics Price Performance

The business has a 50 day moving average price of $15.56 and a 200 day moving average price of $26.06. The firm has a market capitalization of $1.30 billion, a P/E ratio of -3.23 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,387 shares of company stock worth $142,789. Company insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in Dyne Therapeutics during the third quarter valued at about $34,000. Point72 DIFC Ltd bought a new position in Dyne Therapeutics during the third quarter valued at about $36,000. US Bancorp DE increased its stake in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the period. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics during the fourth quarter valued at about $50,000. Finally, KBC Group NV increased its stake in Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after acquiring an additional 751 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.